|Day's Range||64.82 - 65.21|
|52 Week Range||55.10 - 66.80|
|PE Ratio (TTM)||41.38|
|Dividend & Yield||1.88 (2.90%)|
|1y Target Est||N/A|
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be presented ...
Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others
Cambridge cancer drug developer Enumeral could be forced to downsize, file for bankruptcy or sell its assets unless it quickly raises additional capital, the company said this week. Amid the cash crunch, Enumeral said it is “exploring a range of potential transactions.” According to the company, that could include a public or private offering, debt financing, collaborations and licensing deals, or a potential merger or asset sale. A representative for Enumeral did not immediately respond to an interview request on Friday.